Expression of MFF and its biological effects in hepatocellular carcinoma

Abstract

Abstract:ObjectiveTo evaluate the expression of mitochondrial fission factor (MFF) and its biological effects in the progression of hepatocellular carcinoma (HCC). Methods①Quantitative realtime PCR (qPCR), Western blotting and immunohistochemistry analysis were used to detect the expression levels of MFF in HCC tumor tissues and cell lines. ②The effect of MFF knockdown on proliferation of HCC cells was analyzed by methyl thiazolyl tetrazolium (MTT) and colony formation assays in siCtrl, siMFF#1, siMFF#2 groups. ③The effect of MFF knockdown on apoptosis of HCC cells was analyzed by apoptosis assay with Annexin ⅤFITC and PI. Results①The MFF expression was higher in tumor tissues compared with tumoradjacent normal tissues ［mRNA level M(QR): 0.292(0.443) vs. 0.235(0.333), Z=-4.166, P＜0.001; protein level M(QR): 5.414 (4.545) vs. 3.120 (3.955), Z=-3.961， P＜0.001)］. The MFF expression was higher in HCC cell lines compared with normal liver cell line. ②RNA interferencemediated knockdown of MFF inhibited proliferation of HCC cells (siCtrl vs. siMFF#1: 5.29±0.34 vs. 3.34±0.37, P=0.014; siCtrl vs. siMFF#2: 5.29±0.34 vs. 3.09±0.40, P=0.010). RNA interferencemediated knockdown of MFF inhibited colony formation of HCC cells (siCtrl vs. siMFF#1: 95.35±21.20 vs. 37.56±10.61, P=0.003; siCtrl vs. siMFF#2: 95.35±21.20 vs. 41.23±10.82, P=0.004). ③RNA interferencemediated knockdown of MFF induced apoptosis of HCC cells (siCtrl vs. siMFF#1: 9.56%±1.70% vs. 20.08%±2.03%, P＜0.001; siCtrl vs. siMFF#2: 9.56%±1.70% vs. 21.14%±1.38%, P＜0.001). ConclusionMFF is overexpressed in HCC, which accelerates cell proliferation and suppresses apoptosis, indicating that MFF can serve as a potential oncogene and drug target in HCC treatment.

Key words:Liver neoplasms,Cell proliferation,Apoptosis,Mitochondrial fission factor

Li Bo*, Zhang Jiansheng, Li Jiaqi, Yang Yi, Zhang Hongxin, Mou Jiao. Expression of MFF and its biological effects in hepatocellular carcinoma[J]. Journal of International Oncology, 2018, 45(1): 16-.

References

［1］ Chandel NS. Evolution of mitochondria as signaling organelles［J］. Cell Metab, 2015, 22(2): 204206. DOI: 10.1016/j.cmet.2015.05.013. ［2］ Serasinghe MN, Chipuk JE. Mitochondrial fission in human diseases［J］. Handb Exp Pharmacol, 2017, In press. DOI: 10.1007/164_2016_38. ［3］ Mishra P, Chan DC. Mitochondrial dynamics and inheritance during cell division, development and disease［J］. Nat Rev Mol Cell Biol, 2014, 15(10): 634646. DOI: 10.1038/nrm3877. ［4］ Maycotte P, MarínHernández A, GoyriAguirre M, et al. Mitochondrial dynamics and cancer［J］. Tumour Biol, 2017, 39(5): 1010428317698391. DOI: 10.1177/1010428317698391. ［5］ Prieto J, Torres J. Mitochondrial dynamics: in cell reprogramming as it is in cancer［J］. Stem Cells Int, 2017, 2017: 8073721. DOI: 10.1155/2017/8073721. ［6］ Liu R, Chan DC. The mitochondrial fission receptor Mff selectively recruits oligomerized Drp1［J］. Mol Biol Cell, 2015, 26(24): 44664477. DOI: 10.1091/mbc.E15080591. ［7］ Kasahara A, Scorrano L. Mitochondria: from cell death executioners to regulators of cell differentiation［J］. Trends Cell Biol, 2014, 24(12): 761770. DOI: 10.1016/j.tcb.2014.08.005. ［8］ Lee H, Yoon Y. Mitochondrial fission and fusion［J］. Biochem Soc Trans, 2016, 44(6): 17251735. DOI: 10.1042/BST20160129. ［9］ van der Bliek AM, Shen Q, Kawajiri S. Mechanisms of mitochondrial fission and fusion［J］. Cold Spring Harb Perspect Biol, 2013, 5(6). pii: a011072. DOI: 10.1101/cshperspect.a011072. ［10］ Schrepfer E, Scorrano L. Mitofusins, from mitochondria to metabolism［J］. Mol Cell, 2016, 61(5): 683694. DOI: 10.1016/j.molcel.2016.02.022. ［11］ Palmer CS, Elgass KD, Parton RG, et al. Adaptor proteins MiD49 and MiD51 can act independently of Mff and Fis1 in Drp1 recruitment and are specific for mitochondrial fission［J］. J Biol Chem, 2013, 288(38): 2758427593. DOI: 10.1074/jbc.M113.479873. ［12］ Yu R, Liu T, Jin SB, et al. MIEF1/2 function as adaptors to recruit Drp1 to mitochondria and regulate the association of Drp1 with Mff［J］. Sci Rep, 2017, 7(1): 880. DOI: 10.1038/s4159801700853x. ［13］ Senft D, Ronai ZA. Regulators of mitochondrial dynamics in cancer［J］. Curr Opin Cell Biol, 2016, 39: 4352. DOI: 10.1016/j.ceb.2016.02.001. ［14］ Trotta AP, Chipuk JE. Mitochondrial dynamics as regulators of cancer biology［J］. Cell Mol Life Sci, 2017, 74(11): 19992017. DOI: 10.1007/s0001801624513. ［15］ Rehman J, Zhang HJ, Toth PT, et al. Inhibition of mitochondrial fission prevents cell cycle progression in lung cancer［J］. FASEB J, 2012, 26(5): 21752186. DOI: 10.1096/fj.11196543. ［16］ InoueYamauchi A, Oda H. Depletion of mitochondrial fission factor DRP1 causes increased apoptosis in human colon cancer cells［J］. Biochem Biophys Res Commun, 2012, 421(1): 8185. DOI: 10.1016/j.bbrc.2012.03.118. ［17］ Cheng CT, Kuo CY, Ouyang C, et al. Metabolic stressinduced phosphorylation of KAP1 Ser473 blocks mitochondrial fusion in breast cancer cells［J］. Cancer Res, 2016, 76(17): 50065018. DOI: 10.1158/00085472.CAN152921. ［18］ Zhou J, Li G, Zheng Y, et al. A novel autophagy/mitophagy inhibitor liensinine sensitizes breast cancer cells to chemotherapy through DNM1Lmediated mitochondrial fission［J］. Autophagy, 2015, 11(8): 12591279. DOI: 10.1080/15548627.2015.1056970. ［19］ Huang Q, Zhan L, Cao H, et al. Increased mitochondrial fission promotes autophagy and hepatocellular carcinoma cell survival through the ROSmodulated coordinated regulation of the NFκB and TP53 pathways［J］. Autophagy, 2016, 12(6): 9991014. DOI: 10.1080/15548627.2016.1166318. ［20］ Zhan L, Cao H, Wang G, et al. Drp1mediated mitochondrial fission promotes cell proliferation through crosstalk of p53 and NFκB pathways in hepatocellular carcinoma［J］. Oncotarget, 2016, 7(40): 6500165011. DOI: 10.18632/oncotarget.11339.

[1]	Chen Hongjian, Zhang Suqing.Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients[J]. Journal of International Oncology, 2024, 51(6): 344-349.
[2]	Ren Lu, Xie Xiaoli, Zhang Kun, Wang Lijuan.Effects and mechanisms of dihydroartemisinin combined with carfilzomib on the activity， proliferation， and apoptosis of multiple myeloma cells[J]. Journal of International Oncology, 2024, 51(3): 129-136.
[3]	Peng Qin, Cai Yuting, Wang Wei.Advances on KPNA2 in liver cancer[J]. Journal of International Oncology, 2024, 51(3): 181-185.
[4]	Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan.Research progress on the histopathological growth patterns of colorectal liver metastasis[J]. Journal of International Oncology, 2024, 51(2): 114-118.
[5]	Zhang Keping, Zhao Yongsheng, Yang Juan, Fu Maoyong.Chlorogenic acid induces mitochondrial dysfunction in lung cancer A549 cells by inhibiting the PI3K-Akt pathway[J]. Journal of International Oncology, 2024, 51(1): 21-28.
[6]	Xiang Yuling, Tan Jiajie, Xiong Yuanguo, Zhao Lirong, Li Chen, Zhang Hong.Effects of Anhydroicaritin on the proliferation， migration and apoptosis of hepatocellular carcinoma cells[J]. Journal of International Oncology, 2023, 50(9): 513-519.
[7]	Feng Dongxu, Wu Wei, Gao Pingfa, Wang Jun, Shi Lijuan, Chen Dawei, Li Wenbing, Zhang Meifeng.Effects of miR-451 on glycolysis and apoptosis of breast cancer cells by regulating Rho/ROCK1 pathway[J]. Journal of International Oncology, 2023, 50(8): 449-456.
[8]	Wu Jiali, Zhang Jiahui, Zhang Ping, Xiao Xinyue, Li Rui, Zhang Hongyu.Mechanism of Bcl-2 BH4 selective inhibitor BDA-366 on NK/T cell lymphoma cells[J]. Journal of International Oncology, 2023, 50(7): 413-418.
[9]	Yang Ya, Wang Huili, Liu Yan, Guo Jinfeng, Wang Chunxia, Lyu Min, Shan Changping.Effects of GCSH gene on proliferation and apoptosis of gastric cancer SNU-1 cells[J]. Journal of International Oncology, 2023, 50(5): 257-262.
[10]	Quan Zhenhao, Xu Feipeng, Huang Zhe, Huang Xianjin, Chen Rihong, Sun Kaiyu, Hu Xu, Lin Lin.lncRNA FTX silencing inhibits gastric cancer cell proliferation through the miR-22-3p/NLRP3 inflammasome pathway[J]. Journal of International Oncology, 2023, 50(4): 202-207.
[11]	Li Jiaxuan, Feng Yinglu.Mechanism of action of glucocorticoid receptors in the growth of hepatoma cells[J]. Journal of International Oncology, 2023, 50(4): 241-243.
[12]	Zhu Yi, Chen Jian.Mechanism of hydrogen sulfide in tumorigenesis and development and its donor-mediated anti-tumor effects[J]. Journal of International Oncology, 2023, 50(12): 729-733.
[13]	He Ting, Wang Xi, Zhang Huizhong, Liu Xinyang, Wang Huiping, Dong Ke.Diagnostic value of serum TIM-3 in patients with liver cancer[J]. Journal of International Oncology, 2022, 49(9): 537-542.
[14]	Lian Haiwei, Yang Shuorui, Liu Renzhong.Mechanism study on regulation of glioblastoma cell proliferation and apoptosis by sciadopitysin combined with CX-4945 through Notch1 pathway[J]. Journal of International Oncology, 2022, 49(6): 321-326.
[15]	Yang Ya, Ning Xiaofei, Li Bingliang, Yao Hui, Shan Changping, Lyu Min.Study on the mechanism of procyanidin mediated anti gastric cancer SNU-1 cell line by inducing the production of reactive oxygen species[J]. Journal of International Oncology, 2022, 49(5): 257-262.